Literature DB >> 16339677

Treatment of hepatitis C virus infection in thalassemia.

Ellen Butensky1, Zahra Pakbaz, Drucilla Foote, Mark C Walters, Elliott P Vichinsky, Paul Harmatz.   

Abstract

Treatment of hepatitis C virus (HCV) in the general population has improved over the last decade. Patients treated with peginterferon alfa (PegIFN) and ribavirin (RBV) combination therapy demonstrate overall 50-55% sustained viral response (SVR) with rates as high as 80% in patients with genotypes 2 and 3. Because RBV induces hemolysis and subsequently increases blood transfusion requirements, combination therapy has been considered contraindicated for hemoglobinopathies. This report reviews the response to interferon alfa and RBV (IFN/RBV) and PegIFN/RBV combination therapies in patients treated in the Northern California Comprehensive Thalassemia Center. A total of six thalassemia major patients were treated with IFN/RBV (n = 5; age: 4-38 years) or with PegIFN/RBV (n = 1; age: 26 years). Quantitative HCV RNA polymerase chain reaction and liver iron level assessment were completed. Transfusion volumes were obtained from patients' medical records. On IFN/RBV combination, four of five patients demonstrated SVR. The one patient on PegIFN/RBV showed end-treatment viral response after 6 months of therapy (genotype 3), but subsequently relapsed. Liver iron pretreatment level ranged from 0.2 to 22 mg/g dry weight, with a mean +/- SD of 7.9 +/- 7.7. Transfusion requirement increased by a median of 43.5% (range: 32-137%). Five of the six patients had liver iron measurements within 1 year following completion of treatment, with quantitative liver iron increasing in two patients by 2.5 mg/g dry weight, decreasing in two patients by 3 and 14 mg/g dry weight, and remaining unchanged in one patient. All patients were able to complete combination therapy, although dose reductions were required. Patients with thalassemia and high iron overload can obtain SVR after combination therapy with rates similar to those in the general population and without significant complications. Although transfusion requirements increased in most patients, iron burden was not necessarily increased.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16339677     DOI: 10.1196/annals.1345.038

Source DB:  PubMed          Journal:  Ann N Y Acad Sci        ISSN: 0077-8923            Impact factor:   5.691


  5 in total

1.  Hepatocellular carcinoma in thalassemia: A critical review.

Authors:  Andrea Mancuso
Journal:  World J Hepatol       Date:  2010-05-27

2.  Ushering a New Era in the Management of Hepatitis C in Children with Hematological Disorders.

Authors:  Meena Sivasankaran; M Venkatadesikalu; V Mythili; Srinivas Sankaranarayanan; Dhaarani Jayaraman; Shivani Patel; Venkateswaran Vellaichamy Swaminathan; Ramya Uppuluri; Revathi Raj
Journal:  Indian J Hematol Blood Transfus       Date:  2018-07-17       Impact factor: 0.900

3.  Efficacy of interferon alpha-2b with or without ribavirin in thalassemia major patients with chronic hepatitis C virus infection: A randomized, double blind, controlled, parallel group trial.

Authors:  Hamid Kalantari; Neda Rad
Journal:  J Res Med Sci       Date:  2010-11       Impact factor: 1.852

4.  Patients with Haemoglobinopathies and Chronic Hepatitis C: A Real Difficult to Treat Population in 2016?

Authors:  Kalliopi Zachou; Pinelopi Arvaniti; Nikolaos K Gatselis; Kalliopi Azariadis; Georgia Papadamou; Eirini Rigopoulou; George N Dalekos
Journal:  Mediterr J Hematol Infect Dis       Date:  2017-01-01       Impact factor: 2.576

5.  Detection of Hepatitis C Virus RNA in Blood and Saliva of Transfusion-Dependent Thalassemia Patients Diagnosed with Hepatitis C.

Authors:  Behzad Hooshmand; Seyed Moayed Alavian; Farnaz Kouhestani; Maryam Firouzmandi; Saeed Reza Motamedian
Journal:  Contemp Clin Dent       Date:  2018 Jan-Mar
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.